Literature DB >> 15126107

Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone.

Ramesh Prabhu1, Virendra Joshi, Robert F Garry, Frank Bastian, Salima Haque, Fredric Regenstein, Swan Thung, Srikanta Dash.   

Abstract

We have established a T7-based model system for hepatitis C virus (HCV) 1a strain, which involves the use of a replication-defective adenovirus that carries the gene for T7 RNA polymerase and a transcription plasmid containing full-length HCV cDNA clone. To facilitate high-level expression of HCV, sub-confluent Huh7 cells were first infected with adenovirus containing the gene for the T7 RNA polymerase and then transfected with the transcription plasmid. As a negative control, part of NS5B gene of this clone was deleted which abolishes the HCV RNA-dependent RNA polymerase and prevents replication of viral RNA. This model produces high levels of structural (core, E1, E2) and nonstructural proteins (NS5), which were detected by Western blot analysis and immunofluorescence assay. Negative-strand HCV RNA was detected only in the wild-type clone in the presence of actinomycin D, and no RNA was detected with the NS5B deleted mutant control. As a practical validation of this model, we showed that IFN alpha-2b selectively inhibits negative-strand RNA synthesis by blocking at the level of protein translation. The inhibitory effect of IFN alpha-2b is not due reduction of transcription by T7 polymerase or due to intracellular degradation of HCV RNA. This in vitro model provides an efficient and reliable means of assaying negative-strand RNA, protein processing, and testing the antiviral properties of interferon.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126107     DOI: 10.1016/j.yexmp.2004.01.004

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  6 in total

Review 1.  Hepatitis C virus experimental model systems and antiviral drug research.

Authors:  Susan L Uprichard
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

2.  Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway.

Authors:  Sidhartha Hazari; Partha K Chandra; Bret Poat; Sibnarayan Datta; Robert F Garry; Timothy P Foster; Gus Kousoulas; Takaji Wakita; Srikanta Dash
Journal:  Virol J       Date:  2010-02-11       Impact factor: 4.099

3.  Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.

Authors:  Andrea K Erickson; Scott Seiwert; Michael Gale
Journal:  Antivir Ther       Date:  2008

4.  Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.

Authors:  Ramesh Prabhu; Nutan Khalap; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

5.  Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes.

Authors:  Ramesh Prabhu; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2006-11-27       Impact factor: 4.099

6.  Refractoriness of hepatitis C virus internal ribosome entry site to processing by Dicer in vivo.

Authors:  Dominique L Ouellet; Isabelle Plante; Vincent Boissonneault; Cherifa Ayari; Patrick Provost
Journal:  J Negat Results Biomed       Date:  2009-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.